Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies

The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation

(2017) Nicole Stadler et al.   HAEMATOLOGICA

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

(2017) Iris de Weerdt et al.   HAEMATOLOGICA

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

(2017) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)

(2017) Elżbieta Iskierka-Jażdżewska et al.   LEUKEMIA & LYMPHOMA

The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation

(2017) Nicole Stadler et al.   HAEMATOLOGICA

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

(2017) Iris de Weerdt et al.   HAEMATOLOGICA

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

(2016) Chaitra S. Ujjani et al.   BLOOD

AtypicalPneumocystis jiroveciipneumonia in previously untreated patients with CLL on single-agent ibrutinib

(2016) Inhye E. Ahn et al.   BLOOD

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

(2016) Dai Maruyama et al.   CANCER SCIENCE

Bias in reporting of randomised clinical trials in oncology

(2016) Francisco E. Vera-Badillo et al.   EUROPEAN JOURNAL OF CANCER

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

(2016) Michael L Wang et al.   LANCET ONCOLOGY

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

(2016) Susan O'Brien et al.   LANCET ONCOLOGY

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

(2016) Asher Chanan-Khan et al.   LANCET ONCOLOGY

Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia

(2016) Richard R. Furman et al.   LEUKEMIA & LYMPHOMA

The FAIR Guiding Principles for scientific data management and stewardship

(2016) Mark D. Wilkinson et al.   Scientific Data

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

(2015) S. M. Jaglowski et al.   BLOOD

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

(2015) J. R. Brown et al.   BLOOD

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

(2015) P. Jain et al.   BLOOD

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus

(2015) S. Herbst et al.   EMBO Molecular Medicine

Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies

(2015) Kensei Tobinai et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials

(2015) Gita Thanarajasingam et al.   JNCI-Journal of the National Cancer Institute

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

(2015) Mohammed Z H Farooqui et al.   LANCET ONCOLOGY

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials

(2015) Gita Thanarajasingam et al.   JNCI-Journal of the National Cancer Institute

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

(2015) Kami J. Maddocks et al.   JAMA Oncology

HemOnc.org: A Collaborative Online Knowledge Platform for Oncology Professionals

(2015) Jeremy L. Warner et al.   Journal of Oncology Practice

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

(2014) K. Maddocks et al.   BLOOD

Interleukin-2-Inducible T-Cell Kinase (ITK) Deficiency - Clinical and Molecular Aspects

(2014) Sujal Ghosh et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

(2014) Anas Younes et al.   LANCET ONCOLOGY

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

(2014) Jan A Burger et al.   LANCET ONCOLOGY

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

(2013) Susan O'Brien et al.   LANCET ONCOLOGY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia

(2009) Hirokazu Kanegane et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE